AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28741967 — intervention group
Group type: COMPARATOR
Intervention: lixisenatide
Number of subjects: 0
Study 24969363 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational support from an interdisciplinary team
Number of subjects: 42
Study 24969363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 23062021 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group (50-60 minutes of yogic practices daily for 42 days)
Number of subjects: 60
Study 23062021 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched hypertensive individuals)
Number of subjects: 60
Study 21993031 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit™ use for 3 months
Number of subjects: 21
Study 18653546 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 26
Study 18653546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROSI)
Number of subjects: 26
Study 18653546 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MET and ROSI
Number of subjects: 26
Study 17329467 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 17329467 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0
Study 17329467 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 17329467 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 17329467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study 17329467 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 17329467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15166574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene nerve block
Number of subjects: 10
Study 15166574 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 10
Study 15166574 — intervention group
Group type: COMPARATOR
Intervention: Current duration (0.05, 0.1, 0.3, 0.5, 1.0 ms)
Number of subjects: 10
Study 11475562 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (Steri-Neb Salamol 2.5 mg) nebulization
Number of subjects: 30
Study 11475562 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 30
Study 11475562 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol nebulization
Number of subjects: 30
Study 9514485 — intervention group
Group type: EXPERIMENTAL
Intervention: Recess/resect procedures
Number of subjects: 105
Study 9514485 — intervention group
Group type: COMPARATOR
Intervention: Lateral rectus recessions
Number of subjects: 105
Study 9514485 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lateral rectus recessions for simulated divergence excess
Number of subjects: 105
Study 9514485 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance/Near difference after surgery
Number of subjects: 105
Study 7822585 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 58
Study 7822585 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study 3155282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 24
Study 3155282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 24
Study 3155282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31713297 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tamoxifen gel
Number of subjects: 150
Study 31713297 — intervention group
Group type: COMPARATOR
Intervention: Oral tamoxifen 10 mg OD
Number of subjects: 150
Study 29957279 — intervention group
Group type: EXPERIMENTAL
Intervention: PCYQ (n = 139)
Number of subjects: 300
Study 29957279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 143)
Number of subjects: 300
Study 27387096 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTCARE intervention
Number of subjects: 79
Study 27387096 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 79
Study 23560645 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (PDT)
Number of subjects: 40
Study 23560645 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive local drug delivery (LDD) with minocycline microspheres
Number of subjects: 40
Study 22077420 — intervention group
Group type: EXPERIMENTAL
Intervention: Iseganan HCl 9 mg/3 ml, administered as a swish and swallow solution, six times daily for 21-28 days.
Number of subjects: 225
Study 22077420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 225
Study 20723873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligaclip
Number of subjects: 30
Study 20723873 — intervention group
Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 30
Study 18937770 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser treatment
Number of subjects: 10
Study 18937770 — intervention group
Group type: COMPARATOR
Intervention: IPL treatment
Number of subjects: 10
Study 15780536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg estradiol and 0.125 mg norethisterone acetate daily
Number of subjects: 266
Study 15780536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 11808971 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib sodium 40 mg b.i.d. for 7 days
Number of subjects: 92
Study 11808971 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 15 mg q.i.d. for 5 days
Number of subjects: 92
Study 11808971 — intervention group
Group type: COMPARATOR
Intervention: placebo for 7 days
Number of subjects: 92
Study 10521549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid in the media of the basilar artery in ALS patients
Number of subjects: 17
Study 10521549 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 17
Study 7782506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product supplemented with Lactobacillus acidophilus strain La1
Number of subjects: 0
Study 7782506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product supplemented with Bifidobacterium bifidum strain Bb 12
Number of subjects: 0
Study 7782506 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no intervention)
Number of subjects: 0
Study 1947550 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 1947550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6967580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (100 mg/kg for five days)
Number of subjects: 26
Study 6967580 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (20 mg/kg for four days)
Number of subjects: 26
Study 6967580 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (20 mg/kg for four days) after ampicillin treatment failure
Number of subjects: 26
Study 6967580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 31901707 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon arrays
Number of subjects: 393
Study 31901707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pie charts
Number of subjects: 393
Study 31901707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar graphs
Number of subjects: 393
Study 31901707 — intervention group
Group type: COMPARATOR
Intervention: No visualization
Number of subjects: 393
Study 30523732 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Temperature Management at 33°C
Number of subjects: 722
Study 30523732 — intervention group
Group type: COMPARATOR
Intervention: Target Temperature Management at 36°C
Number of subjects: 722
Study 28855078 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided de-escalation group (1 week prasugrel followed by 1 week clopidogrel and PFT-guided maintenance therapy)
Number of subjects: 2610
Study 28855078 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment with prasugrel for 12 months)
Number of subjects: 2610
Study 28855078 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided de-escalation group
Number of subjects: 2610
Study 28855078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2610
Study 25877813 — intervention group
Group type: EXPERIMENTAL
Intervention: carnitine‐orotate complex (824 mg, three times daily)
Number of subjects: 78
Study 25877813 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study 23902527 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate primary closure (Group B)
Number of subjects: 600
Study 23902527 — intervention group
Group type: COMPARATOR
Intervention: Wounds left open (Group A)
Number of subjects: 600
Study 21845038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (D group)
Number of subjects: 12163
Study 21845038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (ND group)
Number of subjects: 12163
Study 18703188 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of PRP gel
Number of subjects: 59
Study 18703188 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 59
Study 17234260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg)
Number of subjects: 75
Study 17234260 — intervention group
Group type: COMPARATOR
Intervention: Control (no iron sucrose)
Number of subjects: 75
Study 16398425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pingxiao capsule (PXC) plus endocrinotherapy (ET)
Number of subjects: 142
Study 16398425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pingxiao capsule (PXC) plus chemotherapy
Number of subjects: 142
Study 16398425 — intervention group
Group type: COMPARATOR
Intervention: Endocrinotherapy (ET) alone
Number of subjects: 142
Study 16398425 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 142
Study 12188940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mannitol (approximately 1.4 g/kg)
Number of subjects: 141
Study 12188940 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose mannitol (approximately 0.7 g/kg)
Number of subjects: 141
Study 10214558 — intervention group
Group type: EXPERIMENTAL
Intervention: + (R)-thalidomide
Number of subjects: 6
Study 10214558 — intervention group
Group type: EXPERIMENTAL
Intervention: - (S)-thalidomide
Number of subjects: 6
Study 10214558 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic thalidomide
Number of subjects: 6
Study 10214558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 158
Study 7649593 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 158
Study 7649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 158
Study 7649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 158
Study 7649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 158
Study 7649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 158
Study 7649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 158
Study 2750828 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch retropubic urethropexy
Number of subjects: 289
Study 2750828 — intervention group
Group type: COMPARATOR
Intervention: Pereyra procedure
Number of subjects: 289
Study 2750828 — intervention group
Group type: COMPARATOR
Intervention: anterior colporrhaphy
Number of subjects: 289
Study 345433 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin added to dialysis solution
Number of subjects: 9
Study 345433 — intervention group
Group type: COMPARATOR
Intervention: No heparin added to dialysis solution
Number of subjects: 9
Study 31445052 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTED AM
Number of subjects: 12
Study 31445052 — intervention group
Group type: EXPERIMENTAL
Intervention: FED AM
Number of subjects: 12
Study 31445052 — intervention group
Group type: EXPERIMENTAL
Intervention: FED PM
Number of subjects: 12
Study 31445052 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTED PM
Number of subjects: 12
Study 31445052 — intervention group
Group type: COMPARATOR
Intervention: FED trials
Number of subjects: 12
Study 31445052 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTED trials
Number of subjects: 12
Study 31445052 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-lunch appetite
Number of subjects: 12
Study 31445052 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h post-energy intake
Number of subjects: 12
Study 27800664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-provided services
Number of subjects: 48
Study 27800664 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 48
Study 27571048 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment plus usual care
Number of subjects: 2717
Study 27571048 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2717
Study 24432992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tx-RAI group (20 subjects who underwent total thyroidectomy and (131)I ablation after recombinant human TSH stimulation)
Number of subjects: 40
Study 24432992 — intervention group
Group type: COMPARATOR
Intervention: Tx group (20 subjects who underwent total thyroidectomy alone)
Number of subjects: 40
Study 22023022 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent alcohol and smoking treatment
Number of subjects: 96
Study 19852293 — intervention group
Group type: EXPERIMENTAL
Intervention: Guishen Zhiyang Recipe (GZR)
Number of subjects: 60
Study 19852293 — intervention group
Group type: COMPARATOR
Intervention: Fuyang Granule (Control)
Number of subjects: 60
Study 17688969 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/gemcitabine combination therapy
Number of subjects: 0
Study 17688969 — intervention group
Group type: COMPARATOR
Intervention: docetaxel monotherapy
Number of subjects: 0
Study 15730812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 20
Study 15730812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 15730812 — intervention group
Group type: COMPARATOR
Intervention: DBT and Control group
Number of subjects: 20
Study 11507733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostane (herbal formulation) at a dose of two tablets a day for 1 year
Number of subjects: 70
Study 11507733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostane (herbal formulation)
Number of subjects: 70
Study 9928566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation (surgery or radiation)
Number of subjects: 0
Study 9928566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation plus chemotherapy
Number of subjects: 0
Study 9928566 — intervention group
Group type: COMPARATOR
Intervention: Ovarian ablation
Number of subjects: 0
Study 9928566 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 7851270 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 23
Study 7851270 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM patients with altered urinary albumin excretion rate (AER > or = 20 micrograms/min)
Number of subjects: 23
Study 3194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information provided
Number of subjects: 270
Study 3194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive information provided
Number of subjects: 270
Study 3194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both visual and proprioceptive information provided
Number of subjects: 270
Study 3194047 — intervention group
Group type: EXPERIMENTAL
Intervention: No information provided
Number of subjects: 270
Study 3194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual conditions
Number of subjects: 270
Study 3194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 7 and 11 years
Number of subjects: 270
Study 3194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondominant hand used by girls
Number of subjects: 270
Study 28627186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterex Diabetic® (EF)
Number of subjects: 17
Study 28627186 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucerna SR® (GF)
Number of subjects: 17
Study 28627186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas (GF and EF)
Number of subjects: 17
Study 25527657 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet (whole-grain products, fatty fish, and bilberries)
Number of subjects: 106
Study 25527657 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain-enriched diet (same grain products as in HD, no change in fish or berry consumption)
Number of subjects: 106
Study 25527657 — intervention group
Group type: COMPARATOR
Intervention: Control diet (refined-wheat breads with restrictions on fish and berries)
Number of subjects: 106
Study 23206691 — intervention group
Group type: EXPERIMENTAL
Intervention: All-arthroscopic (AA) rotator cuff repair
Number of subjects: 100
Study 23206691 — intervention group
Group type: COMPARATOR
Intervention: Mini-open (MO) rotator cuff repair
Number of subjects: 100
Study 21532512 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 59
Study 21532512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow-dose estradiol vaginal ring
Number of subjects: 59
Study 21532512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oxybutynin and estradiol vaginal ring)
Number of subjects: 59
Study 18453510 — intervention group
Group type: EXPERIMENTAL
Intervention: Herba Artemisiae annuae (Aa) tea preparation
Number of subjects: 19
Study 18453510 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 19
Study 16554313 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 68
Study 16554313 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Myocardial Laser Revascularization (PMR)
Number of subjects: 68
Study 12648191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose (LD) remifentanil (0.13 microg kg‐1 x min‐1)
Number of subjects: 18
Study 12648191 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (HD) remifentanil (0.39 microg kg‐1 x min‐1)
Number of subjects: 18
Study 16114784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg t.i.d.
Number of subjects: 130
Study 16114784 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg t.i.d.
Number of subjects: 130
Study 10517426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oseltamivir (100 mg once daily, 100 mg twice daily)
Number of subjects: 117
Study 10517426 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 117
Study 10517426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oseltamivir groups (n = 56)
Number of subjects: 117
Study 10517426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 117
Study 7862369 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions during surgery or within 30 days
Number of subjects: 265
Study 7862369 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusions
Number of subjects: 265
Study 7862369 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions
Number of subjects: 265
Study 2285620 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine heparin
Number of subjects: 113
Study 2285620 — intervention group
Group type: COMPARATOR
Intervention: Bovine heparin
Number of subjects: 113
Study 7363796 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of quinidine bisulphate
Number of subjects: 10
Study 7363796 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine treatment
Number of subjects: 10
Study 7363796 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 7363796 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine and digitoxin therapy
Number of subjects: 10
Study 30688760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group cognitive behavior therapy (M-gCBT)
Number of subjects: 31
Study 30688760 — intervention group
Group type: COMPARATOR
Intervention: Education support group therapy
Number of subjects: 31
Study 27803960 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery (RS)
Number of subjects: 184
Study 27803960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy (FSRT)
Number of subjects: 184
Study 27803960 — intervention group
Group type: COMPARATOR
Intervention: Radiosurgery (RS) vs. Fractionated stereotactic radiotherapy (FSRT)
Number of subjects: 184
Study 27803960 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) after RT
Number of subjects: 184
Study 27803960 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 184
Study 27803960 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient survey outcomes
Number of subjects: 184
Study 25043337 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 at 60 mg
Number of subjects: 90
Study 25043337 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 at 90 mg
Number of subjects: 90
Study 25043337 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000
Number of subjects: 90
Study 25043337 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 at 60 mg and 90 mg
Number of subjects: 90
Study 22932339 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1034702 (8 mg)
Number of subjects: 20
Study 22932339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21455123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 81
Study 21455123 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 81
Study 18996011 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback magnification at 1 x, 4 x, 8 x, 16 x, 32 x, 48 x, and 64 x on a non-compliant surface
Number of subjects: 0
Study 18996011 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback magnification at 1 x, 4 x, 8 x, 16 x, 32 x, 48 x, and 64 x on a foam surface
Number of subjects: 0